ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1776

Animal Models of Pediatric MOGAD

Yike Jiang1, Elliot Lin2, Estefany Reyes2, Devon DiPalma2, Sundar Khadka2, Heather Van Mater2 and Mari Shinohara2, 1Duke Univerisity, Durham, NC, 2Duke University, Durham, NC

Meeting: ACR Convergence 2024

Keywords: Animal Model, Autoantibody(ies), Brain, Mouse Models, Other, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a devastating demyelinating disease that disproportionally affects children. Discovered in 2018, MOGAD is now internationally recognized as distinct from other autoimmune demyelinating conditions like multiple sclerosis and neuromyelitis optica. The clinical presentation of MOGAD is highly variable, including optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), cerebral cortical encephalitis, and FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES). The diagnosis of MOGAD requires detecting serum IgG1 to MOG in its conformational form using cell-based assays. However, the pathologic role of anti-MOG IgG1 is unclear, and there is a critical need for models of pediatric MOGAD to study immunopathogenesis. Our objective is to establish animal models of pediatric MOGAD. We sought to recapitulate three core aspects of pediatric MOGAD in our model system: 1) inflammatory demyelination in the CNS, 2) anti-MOG IgG1 in the serum, and 3) early age of onset.

Methods: We used two animal models using 4-5 week-old mice: The first model is to immunize C57BL/6 (B6) mice with MOG35-55 peptide along with IV injection of anti-MOG IgG1 (8-18C5), and the second model is to immunize IgHMOG mice, MOG-specific Ig heavy-chain knock-in mice, with MOG35-55 peptide. We established a flow cytometric cell-based assay to measure conformation-specific anti-MOG, paralleling the clinical test. We performed immunofluorescent microscopy to measure demyelination and flow cytometry to measure CNS immune infiltration.

Results: For the first B6 model, a single injection of anti-MOG IgG1 exacerbates EAE score with worse demyelination in the spinal cord and optic nerves. Because MOG immunization did not enhance anti-MOG IgG1 generation, the phenotype was attributed to the injection of anti-MOG IgG1. For the second IgHMOG mice model, IgHMOG mice showed an earlier disease onset and a greater degree of demyelination in the spinal cord, compared to wild-type mice. IgHMOG also has greater retinal swelling, as analyzed by optical coherence tomography (OCT), recapitulating a human MOGAD clinical finding. At the peak of EAE score, IgHMOG mice have increased infiltration of CD4+ and CD8+ T lymphocytes and NK cells in the brain and optic nerves.    

Conclusion: Exacerbated EAE scores and optic nerve inflammation in mice with enhanced anti-MOG IgG1 in two animal models recapitulated core aspects of pediatric MOGAD. Using these models, we will further analyze MOGAD phenotypes.


Disclosures: Y. Jiang: None; E. Lin: None; E. Reyes: None; D. DiPalma: None; S. Khadka: None; H. Van Mater: None; M. Shinohara: Ono Pharmaceuticals, 5.

To cite this abstract in AMA style:

Jiang Y, Lin E, Reyes E, DiPalma D, Khadka S, Van Mater H, Shinohara M. Animal Models of Pediatric MOGAD [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/animal-models-of-pediatric-mogad/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/animal-models-of-pediatric-mogad/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology